G1 Therapeutics Inc R&D Day Transcript
Good morning everyone. I am Will Roberts, Vice President of Corporate Communications and Investor Relations here at G1. On behalf of the entire team, I'm very excited to welcome you to our virtual 2022 R&D Day Innovations in Oncology, the Science of trilaciclib. We have a packed agenda this morning, which would run about 1.5 hours or so and I'll review it momentarily. But before I do, I want to remind you that today's webcast has contained forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by those forward-looking statements.
For more information on those forward-looking statements, please refer to our filings with the Securities and Exchange Commission. Any forward-looking statements represent our views as of today, September 15, 2022. I'll remind you that although we're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
